As expected, the results revealed that the average IOD of PDLIM3 immunostaining in gastric tumors (41.7 ± 16.5) was significantly stronger than in matched nontumor samples (19.5 ± 10.8) (P < 0.001). This evidence concerns the gene PDLIM3 and gastric neoplasm.